Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy

International Journal of Gynecological Cancer

Volumn 19, Issue 1, 2009, Pages 79-83

  Mereu, Liliana ^a   Tateo, Saverio ^b   Klersy, Catherine ^c   Gabellotti, Eva Martinotti ^b   Polatti, Franco ^b  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b Department of Obstetrics and Gynecology ^*  (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Chemotherapy; Ovarian cancer; Prognostic index; Venous thromboembolism

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSE; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; AGED; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; OVARY TUMOR;

AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 65649110455     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGJ.0b013e318199035e     Document Type: Article

References (25)

1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism. A population-based case-control study. Arch Intern Med. 2000;160:809-815.
2. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thomboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285-291.
3. Thodiyl PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002; 87:1076-1077.
4. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341:793-800.
5. Turpie AGG, Leizorovicz A. Prevention of venous thromboembolism in medically ill patients: a clinical update. Postgrad Med J. 2006; 82:806-809.
6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338SY400S.
7. Rogers JS, Murgo AJ, Fontana JA, et al. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988; 6:276-281.
8. Bertomeu MC, Gallo S, Lauri D, et al. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Metastasis. 1990; 8:511-518.
9. Cardiovascular Disease Educational and Research Trust; Cyprus Cardiovascular Disease educational and Research Trust; European Venous Forum; et al. Prevention and treatment of venous thromboembolism. International Consensus Statement. Int Angiol. 2006;25:101-161.
10. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994;343:886-889.
11. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005;99:119-125.
12. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404-407.
13. Goodnough LT, Saito H, Manni A, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer. 1984;54:1264-1268.
14. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996;14:2731-2737.
15. Brandes AA, Scelzi E, Salmistraro G, et al. Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer. 1997;33:1592-1596.
16. Cheruku R, Tapazoglou E, Ensley J, et al. The incidence and significance of thromboembolic complications in patients with high grade gliomas. Cancer. 1991;68:2621-2624.
17. Shapiro JD, Harold N, Takimoto C, et al. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. Clin Cancer Res. 1999;5:2399-2408.
18. Otten HMB, Mathijssen J, Cate Ht, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy Arch Intern Med. 2004;164:190-194.
19. Lyman GH, Khorana AA, Falanga A, et al. ASCO: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490-5505.
20. von Tempelhoff GF, Dietrich M, Niemann F, et al. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997;77:456-461.
21. Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105:784-790.
22. Matsuura Y, Robertson G, Marsden DE, et al. Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol. 2007;104:406-410.
23. Tateo S, Mereu L, Salamano S, et al. Clear cell ovarian cancer in stage I disease: high risk of thromboembolic events at diagnosis Int J Gynecol Cancer. 2006;16:674.
24. Jacobson GM, Kamath RS, Smith BJ, et al. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol. 2005;96:470-474.
25. Kakkar AK, Levine M, Pinedo HM, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003; 8:381-388.